IL217013B - Recombinant rsv antigens - Google Patents
Recombinant rsv antigensInfo
- Publication number
- IL217013B IL217013B IL217013A IL21701311A IL217013B IL 217013 B IL217013 B IL 217013B IL 217013 A IL217013 A IL 217013A IL 21701311 A IL21701311 A IL 21701311A IL 217013 B IL217013 B IL 217013B
- Authority
- IL
- Israel
- Prior art keywords
- recombinant rsv
- rsv antigens
- antigens
- recombinant
- rsv
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21996409P | 2009-06-24 | 2009-06-24 | |
| US33456810P | 2010-05-13 | 2010-05-13 | |
| PCT/EP2010/059008 WO2010149745A1 (en) | 2009-06-24 | 2010-06-24 | Recombinant rsv antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL217013A0 IL217013A0 (en) | 2012-02-29 |
| IL217013B true IL217013B (en) | 2018-02-28 |
Family
ID=42670494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL217013A IL217013B (en) | 2009-06-24 | 2011-12-15 | Recombinant rsv antigens |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9492531B2 (OSRAM) |
| EP (1) | EP2445526B1 (OSRAM) |
| JP (2) | JP6062245B2 (OSRAM) |
| KR (1) | KR101696002B1 (OSRAM) |
| CN (1) | CN102481359B (OSRAM) |
| AU (2) | AU2010264688A1 (OSRAM) |
| BR (1) | BRPI1015917A2 (OSRAM) |
| CA (1) | CA2766211A1 (OSRAM) |
| CL (1) | CL2011003273A1 (OSRAM) |
| CO (1) | CO6480978A2 (OSRAM) |
| CR (1) | CR20120025A (OSRAM) |
| CY (1) | CY1117673T1 (OSRAM) |
| DK (1) | DK2445526T3 (OSRAM) |
| DO (1) | DOP2011000389A (OSRAM) |
| EA (1) | EA023054B1 (OSRAM) |
| ES (1) | ES2583257T3 (OSRAM) |
| HR (1) | HRP20160798T1 (OSRAM) |
| HU (1) | HUE028085T2 (OSRAM) |
| IL (1) | IL217013B (OSRAM) |
| MA (1) | MA33449B1 (OSRAM) |
| MX (1) | MX2012000035A (OSRAM) |
| PE (1) | PE20121541A1 (OSRAM) |
| PL (1) | PL2445526T3 (OSRAM) |
| PT (1) | PT2445526T (OSRAM) |
| SG (1) | SG176829A1 (OSRAM) |
| SI (1) | SI2445526T1 (OSRAM) |
| UA (1) | UA111141C2 (OSRAM) |
| WO (1) | WO2010149745A1 (OSRAM) |
| ZA (1) | ZA201109199B (OSRAM) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2222710T1 (sl) | 2007-12-24 | 2016-11-30 | Id Biomedical Corporation Of Quebec | Rekombinatni RSV antigeni |
| DK2370099T3 (en) * | 2008-12-09 | 2016-08-01 | Novavax Inc | Rsv f modified proteins and methods of their use |
| MX2012000036A (es) * | 2009-06-24 | 2012-02-28 | Glaxosmithkline Biolog Sa | Vacuna. |
| SG178026A1 (en) | 2009-07-15 | 2012-03-29 | Novartis Ag | Rsv f protein compositions and methods for making same |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| BR112013029169B1 (pt) * | 2011-05-13 | 2021-09-28 | Novartis Ag | Polipeptídeo f pré-fusão do vírus sincicial respiratório (rsv), composição imunogênica e uso da mesma |
| CN102294027A (zh) * | 2011-07-26 | 2011-12-28 | 昆明理工大学 | 一种呼吸道合胞病毒f2蛋白亚单位疫苗及其制备方法 |
| WO2013031827A1 (ja) | 2011-08-29 | 2013-03-07 | 国立大学法人徳島大学 | Rsv粘膜ワクチン |
| PT2750683T (pt) | 2011-10-03 | 2018-06-26 | Mx Adjuvac Ab | Nanopartículas, processo de preparação e seu uso como transportadores para moléculas hidrofóbicas anfipáticas no domínio da medicina, incluindo tratamento de cancro e compostos relacionados a alimentos |
| CN102743750B (zh) * | 2012-07-09 | 2013-11-20 | 江苏省农业科学院 | 一种复方免疫增强剂、禽用疫苗及其制备方法 |
| IN2015DN01448A (OSRAM) | 2012-08-01 | 2015-07-03 | Bavarian Nordic As | |
| CA2879939A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Novel method |
| US20140037680A1 (en) * | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| AU2014243756B2 (en) * | 2013-03-13 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| US9060975B2 (en) | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
| CN103204943B (zh) * | 2013-03-20 | 2014-07-23 | 中国科学院武汉病毒研究所 | 呼吸道合胞病毒F蛋白与Fc的融合蛋白及其用途 |
| BR112015025392A2 (pt) * | 2013-04-08 | 2017-10-10 | Medimmune Llc | composição de vacina e método de utilização |
| US10899800B2 (en) | 2013-04-25 | 2021-01-26 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| EP3010931B1 (en) | 2013-06-17 | 2018-06-13 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
| JP6564367B2 (ja) * | 2013-08-05 | 2019-08-21 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 併用免疫原性組成物 |
| US9322037B2 (en) * | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| EP3888676A1 (en) | 2014-06-13 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
| KR102638978B1 (ko) | 2015-07-07 | 2024-02-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
| KR20180026734A (ko) | 2015-07-07 | 2018-03-13 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 융합-전 rsv f 폴리펩티드 |
| PE20181354A1 (es) | 2015-12-23 | 2018-08-22 | Pfizer | Mutantes de proteina f de rsv |
| KR20220041966A (ko) | 2016-04-05 | 2022-04-01 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 용해성 융합-전 rsv f 단백질 |
| EA201892250A1 (ru) | 2016-04-05 | 2019-03-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| WO2017207477A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
| WO2017207480A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
| CN115442571A (zh) * | 2016-09-23 | 2022-12-06 | 伊姆西Ip控股有限责任公司 | 用于视频监控系统的故障恢复方法和装置 |
| TWI683826B (zh) * | 2016-11-22 | 2020-02-01 | 國立臺灣大學 | 重組ｒｓｖ抗原 |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| AU2018269319A1 (en) | 2017-05-15 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| KR102658198B1 (ko) | 2017-05-15 | 2024-04-16 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정한 바이러스 함유 조성물 |
| JP2020519663A (ja) | 2017-05-17 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物 |
| GB2600652B (en) | 2017-05-30 | 2022-11-02 | Glaxosmithkline Biologicals Sa | Novel compositions |
| KR20200018483A (ko) | 2017-06-14 | 2020-02-19 | 비로메틱스 아게 | 호흡기 합포체 바이러스에 대한 방어를 위한 고리형 펩티드 |
| MX2020002876A (es) | 2017-09-15 | 2020-07-22 | Janssen Vaccines & Prevention Bv | Metodo para la induccion segura de inmunidad contra el vsr. |
| KR102700187B1 (ko) * | 2017-09-29 | 2024-08-28 | 에스케이바이오사이언스(주) | 가용성 변형 호흡기 융합세포 바이러스 (ｒｓｖ) ｆ 단백질 항원 |
| CN111670044A (zh) | 2017-12-01 | 2020-09-15 | 葛兰素史密丝克莱恩生物有限公司 | 皂苷纯化 |
| JP7613685B2 (ja) * | 2018-04-17 | 2025-01-15 | キュアバック エスイー | 新規ｒｓｖ ｒｎａ分子及びワクチン接種用組成物 |
| WO2020030572A1 (en) | 2018-08-07 | 2020-02-13 | Glaxosmithkline Biologicals Sa | Processes and vaccines |
| JP2022513025A (ja) | 2018-11-13 | 2022-02-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化された融合前ｒｓｖ ｆタンパク質 |
| AU2019408048A1 (en) | 2018-12-20 | 2021-06-24 | Universität Zürich | Lipopeptide building blocks and synthetic virus-like particles |
| CN113543803B (zh) * | 2019-02-28 | 2024-10-29 | Km生物医药股份公司 | Rsv f/g嵌合疫苗 |
| CN114080393A (zh) | 2019-06-05 | 2022-02-22 | 葛兰素史克生物有限公司 | 皂苷纯化 |
| JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Ｒｓｖ ｆタンパク質生産のための細胞培養工程 |
| CN114685627A (zh) * | 2020-12-28 | 2022-07-01 | 广州更新生物医药科技有限公司 | 一种预防呼吸道合胞病毒的rAAV载体疫苗 |
| MX2023009738A (es) | 2021-02-19 | 2023-08-30 | Janssen Vaccines & Prevention Bv | Antigenos de rsv fb prefusion estabilizados. |
| EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
| CN115772230A (zh) * | 2022-07-18 | 2023-03-10 | 青岛硕景生物科技有限公司 | 一种rsv重组抗原、其制备方法及应用 |
| WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
| TWI888970B (zh) | 2022-10-27 | 2025-07-01 | 美商輝瑞大藥廠 | Rna分子 |
| EP4608441A1 (en) | 2022-10-27 | 2025-09-03 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
| WO2024127181A1 (en) | 2022-12-11 | 2024-06-20 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
| TW202436325A (zh) | 2023-01-18 | 2024-09-16 | 美商輝瑞大藥廠 | 針對呼吸道疾病之疫苗 |
| CN118078975A (zh) * | 2023-03-17 | 2024-05-28 | 成都威斯克生物医药有限公司 | 抗呼吸道合胞病毒感染的疫苗 |
| TW202515531A (zh) | 2023-07-07 | 2025-04-16 | 美商輝瑞股份有限公司 | 兩親性ｔｌｒ７／８佐劑及其用途 |
| EP4520334A1 (en) | 2023-09-07 | 2025-03-12 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| WO2025052001A1 (en) | 2023-09-07 | 2025-03-13 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025163460A2 (en) | 2024-01-30 | 2025-08-07 | Pfizer Inc. | Vaccines against respiratory diseases |
| WO2025186719A1 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions and uses thereof |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
| US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
| WO1989005823A1 (en) | 1987-12-23 | 1989-06-29 | The Upjohn Company | Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| EP0671948B1 (en) | 1992-06-25 | 1997-08-13 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| CA2151597A1 (en) | 1993-01-08 | 1994-07-21 | Robert L. Garlick | Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein |
| DK0689454T4 (da) | 1993-03-23 | 2005-05-30 | Smithkline Beecham Biolog | Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| PL181241B1 (pl) | 1993-11-17 | 2001-06-29 | Deutsche Om Arzneimittel Gmbh | Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| JP3468773B2 (ja) | 1994-07-15 | 2003-11-17 | ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 免疫調節オリゴヌクレオチド |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6060308A (en) * | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
| ES2236946T3 (es) | 1997-09-19 | 2005-07-16 | Wyeth Holdings Corporation | Peptidos derivados de la proteina de union (g) del virus respiratorio sincitial. |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| HUP0102332A3 (en) | 1998-06-08 | 2002-11-28 | Sca Emballage France | Fast flattening packaging |
| DK1091928T3 (da) | 1998-06-30 | 2007-07-23 | Om Pharma | Nye acylerede pseudodipeptider, fremgangsmåde til disses fremstilling og sammensætninger, som indeholder dem |
| PL201482B1 (pl) | 1998-10-16 | 2009-04-30 | Smithkline Beecham Biolog | Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| WO2001046127A1 (fr) | 1999-12-22 | 2001-06-28 | Om Pharma | Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise |
| WO2002042326A1 (en) * | 2000-11-22 | 2002-05-30 | Biota Scientific Management Pty Ltd | A method of expression and agents identified thereby |
| CA2435972C (en) | 2001-01-26 | 2011-09-13 | University Of Lausanne | Matrix attachment regions and methods for use thereof |
| WO2002072012A2 (en) | 2001-03-09 | 2002-09-19 | Id Biomedical Corporation Of Quebec | A novel proteosome-liposaccharide vaccine adjuvant |
| JP4331944B2 (ja) | 2001-04-17 | 2009-09-16 | 大日本住友製薬株式会社 | 新規アデニン誘導体 |
| EP1455700A4 (en) | 2001-11-16 | 2007-02-14 | 3M Innovative Properties Co | METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS |
| US7375180B2 (en) | 2003-02-13 | 2008-05-20 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and Toll-like receptor 8 |
| US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
| RU2375450C2 (ru) | 2003-10-24 | 2009-12-10 | Селексис С.А. | Днк, повышающая продуцирование белка, и ее применение |
| FR2873378A1 (fr) | 2004-07-23 | 2006-01-27 | Pierre Fabre Medicament Sa | Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques |
| GB0422439D0 (en) | 2004-10-08 | 2004-11-10 | European Molecular Biology Lab Embl | Inhibitors of infection |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| US20080233150A1 (en) * | 2006-11-16 | 2008-09-25 | Gale Smith | Respiratory syncytial virus-virus like particle (vlps) |
| EP2181121A4 (en) | 2007-03-21 | 2012-07-11 | Id Biomedical Corp Quebec | CHIMÄRE ANTIGENE |
| WO2008154456A2 (en) * | 2007-06-06 | 2008-12-18 | Nationwide Children's Hospital, Inc. | Methods and compositions relating to viral fusion proteins |
| SI2222710T1 (sl) | 2007-12-24 | 2016-11-30 | Id Biomedical Corporation Of Quebec | Rekombinatni RSV antigeni |
| EA201170217A1 (ru) | 2008-07-18 | 2011-08-30 | АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК | Гибридные полипептидные антигены респираторно-синцитиального вируса |
| MX2012000036A (es) | 2009-06-24 | 2012-02-28 | Glaxosmithkline Biolog Sa | Vacuna. |
-
2010
- 2010-06-24 JP JP2012516746A patent/JP6062245B2/ja not_active Expired - Fee Related
- 2010-06-24 CA CA2766211A patent/CA2766211A1/en not_active Abandoned
- 2010-06-24 EA EA201270063A patent/EA023054B1/ru not_active IP Right Cessation
- 2010-06-24 US US13/378,391 patent/US9492531B2/en not_active Expired - Fee Related
- 2010-06-24 MX MX2012000035A patent/MX2012000035A/es active IP Right Grant
- 2010-06-24 BR BRPI1015917A patent/BRPI1015917A2/pt not_active Application Discontinuation
- 2010-06-24 CN CN201080037770.3A patent/CN102481359B/zh not_active Expired - Fee Related
- 2010-06-24 PL PL10724879T patent/PL2445526T3/pl unknown
- 2010-06-24 MA MA34557A patent/MA33449B1/fr unknown
- 2010-06-24 EP EP10724879.1A patent/EP2445526B1/en active Active
- 2010-06-24 PT PT107248791T patent/PT2445526T/pt unknown
- 2010-06-24 HR HRP20160798TT patent/HRP20160798T1/hr unknown
- 2010-06-24 WO PCT/EP2010/059008 patent/WO2010149745A1/en not_active Ceased
- 2010-06-24 SG SG2011092319A patent/SG176829A1/en unknown
- 2010-06-24 UA UAA201200714A patent/UA111141C2/uk unknown
- 2010-06-24 HU HUE10724879A patent/HUE028085T2/en unknown
- 2010-06-24 DK DK10724879.1T patent/DK2445526T3/en active
- 2010-06-24 KR KR1020127001782A patent/KR101696002B1/ko not_active Expired - Fee Related
- 2010-06-24 PE PE2011002168A patent/PE20121541A1/es not_active Application Discontinuation
- 2010-06-24 SI SI201031234A patent/SI2445526T1/sl unknown
- 2010-06-24 AU AU2010264688A patent/AU2010264688A1/en not_active Abandoned
- 2010-06-24 ES ES10724879.1T patent/ES2583257T3/es active Active
-
2011
- 2011-12-14 ZA ZA2011/09199A patent/ZA201109199B/en unknown
- 2011-12-14 DO DO2011000389A patent/DOP2011000389A/es unknown
- 2011-12-15 IL IL217013A patent/IL217013B/en not_active IP Right Cessation
- 2011-12-22 CL CL2011003273A patent/CL2011003273A1/es unknown
- 2011-12-29 CO CO11181053A patent/CO6480978A2/es unknown
-
2012
- 2012-01-16 CR CR20120025A patent/CR20120025A/es unknown
-
2014
- 2014-07-03 AU AU2014203636A patent/AU2014203636C1/en not_active Ceased
-
2016
- 2016-01-14 JP JP2016005403A patent/JP2016128457A/ja active Pending
- 2016-06-21 CY CY20161100557T patent/CY1117673T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL217013A0 (en) | Recombinant rsv antigens | |
| ZA201004289B (en) | Recombinant rsv antigens | |
| EP2409990A4 (en) | VARIANT OF A CONSTANT ANTIBODY REGION | |
| IL214996A0 (en) | Anti-bcma antibodies | |
| GB0920127D0 (en) | Antibodies | |
| GB0909906D0 (en) | Antibodies | |
| ZA201104545B (en) | Anti-siglec-15 antibody | |
| IL218858A0 (en) | Albumin variants | |
| PT2294202E (pt) | Antigénios gripais recombinantes solúveis | |
| ZA201108526B (en) | Anti-axl antibody | |
| EP2427496A4 (en) | ANTI-VEGF-D ANTIBODIES | |
| HRP20141257T1 (en) | Antibodies against her2 truncated variant ctf-611 | |
| GB0920324D0 (en) | Antibodies | |
| GB0905972D0 (en) | Antibodies against IL-17BR | |
| EP2480578A4 (en) | MODIFICATION OF POLYPEPTIDE | |
| ZA201108446B (en) | FViII-DERIVED PEPTIDES | |
| EP2499256A4 (en) | ANTI-C-MPL ANTIBODIES | |
| IL219948A0 (en) | Polypeptide conjugate | |
| ZA201203722B (en) | Peptide | |
| GB2473934B (en) | Anti-VEEV antibody | |
| GB0914046D0 (en) | Bonding arrangement | |
| GB0917685D0 (en) | Antigenic polypeptide | |
| HK1163543A (en) | Recombinant rsv antigens | |
| GB0908945D0 (en) | Antibodies | |
| GB0911712D0 (en) | Antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| MM9K | Patent not in force due to non-payment of renewal fees |